Summary of the randomized trials of DOACs vs LMWHs in total hip and knee replacement and the effect of nonfatal PE, symptomatic DVT, bleeding requiring reoperation, and major nonfatal bleeding (data adapted from the ACCP guidelines)13
| DOAC . | No. in trials . | RR (95% CI) of nonfatal PE . | RR (95% CI) of symptomatic DVT . | RR (95% CI) of bleeding requiring reoperation . | RR (95% CI) of major nonfatal bleeding . |
|---|---|---|---|---|---|
| Rivaroxaban | 10 869 (7 studies) | RR, 1.34 (0.39-4.6) | RR, 0.41 (0.2-0.83) | RR, 2.03 (0.86-4.83) | RR, 1.58 (0.84-2.97) |
| Dabigatran | 7 377 (4 studies) | RR, 1.22 (0.52-2,85) | RR, 0.70 (0.12-3.91) | RR, 0.98 (0.27-3.54) | RR, 1.06 (0.66-1.72) |
| Apixaban | 11 964 (4 studies) | RR, 1.09 (0.31-3.88) | RR, 0.41 (0.18-0.95) | RR, 0.82 (0.15-4.58) | RR, 0.76 (0.44-1.32) |
| DOAC . | No. in trials . | RR (95% CI) of nonfatal PE . | RR (95% CI) of symptomatic DVT . | RR (95% CI) of bleeding requiring reoperation . | RR (95% CI) of major nonfatal bleeding . |
|---|---|---|---|---|---|
| Rivaroxaban | 10 869 (7 studies) | RR, 1.34 (0.39-4.6) | RR, 0.41 (0.2-0.83) | RR, 2.03 (0.86-4.83) | RR, 1.58 (0.84-2.97) |
| Dabigatran | 7 377 (4 studies) | RR, 1.22 (0.52-2,85) | RR, 0.70 (0.12-3.91) | RR, 0.98 (0.27-3.54) | RR, 1.06 (0.66-1.72) |
| Apixaban | 11 964 (4 studies) | RR, 1.09 (0.31-3.88) | RR, 0.41 (0.18-0.95) | RR, 0.82 (0.15-4.58) | RR, 0.76 (0.44-1.32) |
95% CI, 95% confidence interval; RR, relative risk.